CLINICAL TRIALS

Melanoma Clinical Trials in Montana

10+ recruiting Melanoma trials in Montana, simplified into plain English.

Informational only. Not medical advice. Always consult a qualified healthcare professional.
Data sourced from ClinicalTrials.gov (NLM/NIH).

ACTIVE NOT RECRUITINGPhase 3

Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery

This randomized phase III trial studies ipilimumab to see how well it works compared to high-dose interferon alfa-2b in treating patients with high-risk stage III-IV melanoma that has been removed by surgery. Immunothera

NCT01274338 · Billings
RECRUITING

Assessing Benefits and Harms of Cannabis/Cannabinoid Use Among Cancer Patients Treated in Community Oncology Clinics

This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer

NCT06418204 · Anaconda
ACTIVE NOT RECRUITINGPhase 2

QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

QUILT-3.055 is a Phase 2b, open-label, multicohort study investigating combination immunotherapies in patients with advanced solid tumors who have previously been treated with PD-1/PD-L1 checkpoint inhibitors. The study

NCT03228667 · Billings
ACTIVE NOT RECRUITINGPhase 2

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable). Anti-PD-1

NCT04462406 · Anaconda
ACTIVE NOT RECRUITINGPhase 2

A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma

This phase II trial studies the effect of pembrolizumab alone or in combination with CMP-001 in treating patients with melanoma that can be treated by surgery (operable). Immunotherapy with monoclonal antibodies, such as

NCT04708418 · Missoula
ACTIVE NOT RECRUITINGPhase 3

Study Comparing Investigational Drug HBI-8000 + Nivolumab vs. Placebo + Nivolumab in Patients With Advanced Melanoma

This is a clinical study to compare the efficacy and safety of HBI-8000 combined with nivolumab to Placebo combined with nivolumab in patients with unresectable or metastatic melanoma. A separate open-label cohort of adu

NCT04674683 · Billings
ACTIVE NOT RECRUITINGPhase 2

Dinaciclib in Treating Patients With Stage IV Melanoma

This phase II trial is studying the side effects and how well dinaciclib works in treating patients with stage IV melanoma. Dinaciclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell gr

NCT00937937 · Billings
ACTIVE NOT RECRUITINGPhase 2

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

This phase II MATCH screening and multi-sub-trial studies how well treatment that is directed by genetic testing works in patients with solid tumors, lymphomas, or multiple myelomas that may have spread from where it fir

NCT02465060 · Anaconda
RECRUITING

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) prog

NCT03452774 · Billings
RECRUITINGPhase 1

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selecti

NCT06425926 · Billings

RECOMMENDED RESOURCES FOR MELANOMA

🧬

Color Health

CLIA Certified

Hereditary cancer genetic testing from $99. Understand your inherited risk for breast, ovarian, colon, and other cancers — with genetic counseling included.

Get Tested →

Clinicals AI may earn a referral fee. At no cost to you.

COMMON QUESTIONS

Are there Melanoma clinical trials in Montana?

Yes. Clinicals AI lists 10+ recruiting Melanoma trials in Montana sourced from ClinicalTrials.gov. Browse them above or search across all states.

How do I qualify for a Melanoma trial in Montana?

Eligibility varies by study. Most trials require a confirmed Melanoma diagnosis, fall within a specific age range, and may have restrictions based on prior treatments. Review each listing's criteria and submit a contact request for more details.

Are Melanoma clinical trials free to join?

Most trials cover the investigational treatment and all study-related visits. Some also offer compensation for travel and time. Always confirm the cost structure with the trial coordinator before enrolling.